Related Experiment Video
Updated: Jun 28, 2025

Isolation of Cerebral Capillaries from Fresh Human Brain Tissue
Published on: September 12, 2018
IQGAP2 regulates blood-brain barrier immune dynamics
Ketaki A Katdare1, Andrew Kjar2, Natasha M O'Brown3
1Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA.
Loss of IQGAP2 protein increases immune cell entry into the brain by disrupting blood-brain barrier functions. Reduced IQGAP2 is linked to Alzheimer's disease, highlighting its role in CNS immune privilege.
Area of Science:
- Neuroimmunology
- Cell Biology
- Molecular Biology
Background:
- Brain endothelial cells (BECs) maintain central nervous system (CNS) homeostasis via blood-brain barrier (BBB) functions.
- BECs normally limit leukocyte entry by expressing low adhesion receptor levels, but underlying molecular mechanisms are largely unknown.
Approach:
- Investigated the role of scaffold protein IQ motif containing GTPase activating protein 2 (IQGAP2) in regulating immune cell infiltration across the BBB.
- Utilized mouse and zebrafish models, single-cell RNA sequencing, and immunohistology.
- Analyzed human hippocampal tissue to assess IQGAP2 levels in Alzheimer's disease.
Key Points:
- Loss of Iqgap2 in mice and zebrafish led to increased peripheral leukocyte infiltration into the CNS under homeostatic and inflammatory conditions.
- Iqgap2-deficient BECs displayed a significant inflammatory signature, with upregulated adhesion receptors and antigen-processing machinery.
- Reduced hippocampal IQGAP2 was observed in human Alzheimer's disease tissues.
Conclusions:
- IQGAP2 is a critical regulator of BBB immune privilege.
- IQGAP2 controls immune cell entry into the CNS.
- Dysregulation of IQGAP2 may contribute to neuroinflammation and neurodegenerative diseases like Alzheimer's.
More Related Videos
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
06:19Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
Published on: October 20, 2023